ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial

Permanent link
https://hdl.handle.net/10037/12193
DOI
https://doi.org/10.1186/s12883-017-0851-0
Thumbnail
View/Open
article.pdf (396.7Kb)
(PDF)
Date
2017-04-04
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Holmøy, Trygve; Lindstrøm, Jonas Christoffer; Eriksen, Erik Fink; Steffensen, Linn Hofsøy; Kampman, Margitta Theodora
Abstract
Background:
People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression and to maintain bone health.
Methods:
We assessed the effect of 20,000 IU vitamin D3 weekly compared to placebo on biochemical markers of bone metabolism in 68 persons with relapsing remitting multiple sclerosis.
Results:
Serum levels of 25-hydroxyvitamin D more than doubled in the vitamin D group, and parathyroid hormone decreased in the vitamin D group compared to the placebo group at week 48 and week 96. There was however no effect on bone formation as measured by procollagen type I N propeptide (PINP), or on bone resorption as measured by C-terminal cross-linking telopeptide of type I collagen (CTX1). Neither PINP nor CTX1 predicted bone loss from baseline to week 96.
Conclusions:
These findings corroborate the previously reported lack of effect of weekly high dose vitamin D supplementation on bone mass density in the same patients, and suggest that such vitamin D supplementation does not prevent bone loss in persons with MS who are not vitamin D deficient.
Trial registration:
The trial was registered at ClinicalTrials.gov on April 4 2008, registration number NCT00785473.
Description
Source at: https://doi.org/10.1186/s12883-017-0851-0
Publisher
BioMed Central
Citation
Holmøy, T., Lindstrøm, J. C., Eriksen, E. F., Steffensen, L. H. & Kampman, M. T. (2017). High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology, 17(67), 1-6. https://doi.org/10.1186/s12883-017-0851-0
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)